The collaboration between Sam Rodriques and Andrew White, driven by advancements in AI models like Chat-GPT, led to the establishment of FutureHouse, which focuses on developing specialized AI tools for scientific tasks.

FutureHouse, a philanthropically funded research lab, aims to accelerate scientific research by automating critical tasks such as information retrieval, synthesis, and data analysis through its AI platform.

The founders believe that providing scientists with access to specialized AI agents can help overcome significant bottlenecks in scientific discovery and address urgent global challenges.

Rodriques' inspiration for FutureHouse originated from his PhD research at MIT, where he recognized that the overwhelming volume of scientific literature hampers researchers' ability to develop comprehensive theories.

Researchers have noted a decline in scientific productivity over the past 50 years, attributing this slowdown to the increasing complexity and specialization required in research processes.

FutureHouse plans to enhance its AI agents by integrating tacit knowledge and advanced computational tools to conduct more sophisticated analyses and improve the reproducibility of scientific results.

FutureHouse officially launched its AI platform on May 1, 2025, introducing multiple AI agents designed to streamline the scientific discovery workflow.

On May 20, 2025, FutureHouse showcased a multi-agent workflow that successfully identified a new therapeutic candidate for dry age-related macular degeneration, highlighting the platform's potential.

The founders initially developed distinct AI tools for various scientific tasks, leading to the creation of PaperQA (now Crow) and Has Anyone (now Owl), which assist in literature searches and hypothesis tracking.

Rodriques emphasizes the necessity of building infrastructure that enables AI agents to access and utilize advanced scientific models and tools to facilitate ongoing scientific advancement.

The platform has already shown promising results, with users successfully identifying potential treatments for diseases such as polycystic ovary syndrome and Alzheimer’s by utilizing FutureHouse’s AI agents.